CSIMarket Company Name, Ticker, Customers, else..
 
Zenas Biopharma Inc   (NASDAQ: ZBIO)
 
Price: $27.9400 $0.97 3.597%
Day's High: $29.229999542236328 Week Perf: 3.67 %
Day's Low: $ 26.55 30 Day Perf: -12.63 %
Volume (M): 826,447 52 Wk High: $ 44.60
Volume (M$): $ 0 52 Wk Avg: $26.62
Open: $26.89 52 Wk Low: $13.50



 Market Capitalization (Millions $) 1,763
 Shares Outstanding (Millions) 63
 Employees 167
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -484
 Cash Flow (TTM) (Millions $) 456
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage global biopharmaceutical firm specializing in the development and commercialization of immunology-based therapies for autoimmune diseases. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody that targets B cell lineage to inhibit autoimmune disease activity without depleting B cells. Obexelimab is being developed for multiple autoimmune indications, including IgG4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus. The company is also developing other candidates, including orelabrutinib, a BTK inhibitor for multiple sclerosis, as well as early-stage candidates ZB021 and ZB022 for inflammatory and immunology diseases.


   Company Address: 852 Winter Street Waltham 2451 MA
   Company Phone Number: 271-2954   Stock Exchange / Ticker: NASDAQ ZBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Zenas BioPharma Faces Class Action Amid Financial Struggles A Call to Investors to Take Action

Published Thu, May 29 2025 6:44 PM UTC

ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit for Zenas BioPharma, Inc. Shareholders In a significant development within the pharmaceutical sector, Robbins Geller Rudman & Dowd LLP has issued an investor alert regarding Zenas BioPharma, Inc. (NASDAQ: ZBIO), paving the way for substantial legal action that highlights both potential corp...
Announcement

Investors in Zenas BioPharma Urged to Act Before Deadline Amid Allegations of Misleading Information

Published Sat, Apr 26 2025 10:22 AM UTC

In a significant development for investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO), Rosen Law Firm, a prominent global investor rights law firm, is urging shareholders to secure legal counsel ahead of a critical deadline in a securities class action lawsuit. This comes on the heels of important filings related to the company’s initial public offering (IPO) that took place ...
Management Announcement

Zenas BioPharma Under Fire: Stock Options for New Executives Amid Financial Woes and Legal Scrutiny,

Published Thu, Apr 17 2025 8:20 PM UTC

Zenas BioPharma s Stock Options Riddle Amid Financial ScrutinyBy Author Name | CSI MarketApril 18, 2025 — In a move that has raised eyebrows within the biopharmaceutical community, Zenas BioPharma, Inc. (Nasdaq: ZBIO) announced on April 15, 2025, the granting of nonqualified stock options to two newly hired executives. This decision was made in accordance with Nasdaq’...
Announcement

Financial Compliance and Ethical Standards in Biopharmaceutical firms Analyzing the Situation of Zenas BioPharma, Inc.

Published Fri, Apr 4 2025 6:53 PM UTC

Zenas BioPharma, Inc. (NASDAQ: ZBIO) has recently come under scrutiny due to potential discrepancies in its disclosed business information, which have raised concerns among shareholders and industry analysts alike. This article discusses not only the current financial standing of Zenas BioPharma but also highlights the importance of accurate financial reporting and commun...
Announcement

Investigative Scrutiny on Zenas BioPharma A Call to Empower and Protect Investor Rights

Published Tue, Apr 1 2025 5:47 PM UTC

In a significant development concerning corporate accountability and investor protection, the Rosen Law Firm, a renowned global investor rights law firm, announced its probe into the intricacies surrounding Zenas BioPharma, Inc. (NASDAQ: ZBIO). This investigation, unveiled on April 1, 2025, seeks to assess potential securities claims set forth by shareholders of Zenas BioPha...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1,763.36
Price to Sales (Expected) -
Price to Book 7.14
PEG (TTM) -

Financial Strength Current
Quick Ratio 24.28
Working Capital Ratio 24.44
Leverage Ratio (MRQ) 1.84
Total Debt to Equity 1.2
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -9.83 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) 7.23 $
Cash 25.32 $
Book Value 3.92 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 5,988
Net Income per Employee (TTM) -2,900,503
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -10765.9 %
Net Margin (MRQ) -11145.6 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Zenas Biopharma Inc's Segments
Single Reportable Segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.